The APOE has been identified as a biomarker for prognosis of mild cognitive impairment and AD [45] and for diagnosis of depressive disorder and dementia [46] and used as a biomarker for measuring the efficacy of testosterone in treating AD and mild cognitive impairment [47]. Here, APOE is linked to Cognitive impairment.